LATEST UPDATES » Vol 23, No 04, April 2019 – Career development for researchers       » CRISPR not as precise as thought       » Insomnia spreads among young Chinese       » Chinese HEV vaccine begin clinical trial in U.S       » Eating mushrooms may reduce risk of cognitive decline       » Green tea cuts obesity in mice      
INSIDE INDUSTRY For e-subscribers (PDF)
Vol 22, No 01, January 2018
Drug development companies in APAC need to raise their game to capitalise on the $33bn+ immuno-oncology treatment opportunity

Japan is currently leading the APAC region's PD-(L)1 combination development, but China is on course to outperform Japan in the near future.

Singapore's pharmaceutical market value to reach $1.15 billion by 2021

Singapore's healthcare market is driven by universal access to health insurance schemes and world-class biomedical sciences research facilities. However, the market is still small due to the small population, says GlobalData.

Ryzodeg reduces hypoglycaemia in type 2 diabetic fasting patients

Ryzodeg significantly reduces the risk of low blood sugar in people with type 2 diabetes who fast during Ramadan, by 62%

FDA approves Amgen's Repatha (evolocumab) to prevent heart attack and stroke

Following FDA priority review, Repatha is the only PCSK9 inhibitor approved to reduce risk of heart attack, stroke and coronary revascularization

FDA approves first drug for rare disease, eosinophilic granulomatosis with polyangiitis

Formerly known as the Churg-Strauss Syndrome, it is an autoimmune disease that causes inflammation in the walls of blood vessels

FDA approves first biosimilar for the treatment of certain breast and stomach cancers

Ogivri, a biosimilar to the cancer drug Herceptin, is approved for HER2+ breast cancer and metastatic stomach cancers

FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss

Luxturna is the first gene therapy approved in the U.S. to target a disease caused by mutations in a specific gene.

Singapore institutes collaborate with Samsung Medical Center to improve treatment of liver cancer

This collaboration creates the world's first clinically reliable and robust patient-specific diagnostic and predictive platform to improve treatment of liver cancer. The platform will provide high throughput genomics and drug screening data from a patient's liver cancer sample, to inform timely clinical management.

Globavir announces partnership with Singhealth Duke-NUS Academic Medical Centre to study dengue treatment

Newly established Viral Research and Experimental Medicine Centre (ViREMiCS) will conduct research for the treatment of dengue and chikungunya.

Mundipharma secures exclusive license for the development and commercialisation of PAION's remimazolam in Japan

Mundipharma has entered into an exclusive license agreement with Frankfurt-listed pharmaceuticals company, PAION AG, for the development and commercialisation of its lead medicine candidate, remimazolam, in Japan.

news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
Asia Pacific Biotech News

APBN Editorial Calendar 2019
Taiwan Medical tourism
Marijuana as medicine — Legal marijuana will open up scientific research
Driven by curiosity
Career developments for researchers
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy